LL-37 and Sermorelin Interaction

Synergistic
Mechanism-based 47% confidence

LL-37 and Sermorelin have a synergistic interaction with 47% confidence. LL-37 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

LL-37

Human Cathelicidin | Antimicrobial Peptide

Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically..

Half-life: Short (rapid proteolytic degradation) Typical dose: 0.5-1.6 mg/mL topical gel or 100-150 mcg injectable immune, healing
View full profile

Sermorelin

GHRH Analog | Growth Hormone Releasing Hormone

Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback..

Half-life: 10-12 minutes Typical dose: 200-300mcg per dose (up to 500mcg for athletic performance) growth hormone, weight loss
estrogen receptorghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

Blood Vessels
low
GI Tract
low
Pituitary
low

Frequently Asked Questions

Can I take LL-37 with Sermorelin?

Yes, LL-37 and Sermorelin can generally be taken together. LL-37 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is LL-37 and Sermorelin safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between LL-37 and Sermorelin?

LL-37 and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time LL-37 and Sermorelin?

LL-37 has a half-life of Short (rapid proteolytic degradation) and Sermorelin has a half-life of 10-12 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LL-37 vs Sermorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.